Ceva Sante Animale (PRIVATE.CEVA)

Overall impact
C (54)

Commentary

Ceva Sante Animale is an average overall performer. With a 'C' rating of 53.7 for overall impact (50th percentile compared to all companies), Ceva Sante Animale ranks 218th out of 260 industry peers, behind Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 214 others, and ahead of Azurity Pharmaceuticals, Teva, Collegium Pharmaceutical and 39 others. On top material causes for Ceva Sante Animale's industry (Pharmaceuticals), Ceva Sante Animale performs well in Technology Innovation (87.4 score), Accountable Institutions (95.0), Child and Maternal Health (81.5) and 48 other causes where it received an 'A' score and performs poorly in Equal Pay and Opportunity (37.6 score), Racial Justice and Civil Rights (25.4), Equal Pay and Opportunity (37.6) and 21 other causes where it received a 'D' or 'F' score.
Company
Founded
1999
Employees
7,000
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
France
Share classes
PRIVATE.CEVA
Description
Manufacturer of veterinary pharmaceutical products intended to be used for companion and production animals. The company offers products for cardiology, behavior and locomotion and swine and ruminants as well as for antibiotic therapy and control of reproduction. Additionally, they provide poultry vaccines and vaccination equipment, pharmaceuticals, and disinfectants. Ultimately, this helps health authorities to protect the health of humans and animals.
Material causes
Ethos considers the following causes material for Ceva Sante Animale, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.